Skip to main content
FDA grants breakthrough status to Seattle's T-cell lymphoma drug

Seattle Genetics' Adcetris, or brentuximab vedotin, being developed to treat patients with systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas in a first-line setting, was given breakthrough therapy status by the FDA.

Full Story: